Next Article in Journal
Diagnostic and Prognostic Potential of SH3YL1 and NOX4 in Muscle-Invasive Bladder Cancer
Previous Article in Journal
Antioxidant and Neuroprotective Properties of Selected Pyrrole-Containing Azomethine Compounds in Neurotoxicity Models In Vitro
Previous Article in Special Issue
Differential Urinary Microbiome and Its Metabolic Footprint in Bladder Cancer Patients Following BCG Treatment
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Vaginal Microbiota and Local Immunity in HPV-Induced High-Grade Cervical Dysplasia: A Narrative Review

by
Helena C. J. Schellekens
1,2,
Lotte M. S. Schmidt
1,
Servaas A. Morré
2,3,4,
Edith M. G. van Esch
5 and
Peggy J. de Vos van Steenwijk
1,2,*
1
Department of Gynecology and Obstetrics, Maastricht University Medical Centre (MUMC+), 6229 HX Maastricht, The Netherlands
2
GROW—School for Oncology and Reproduction, Maastricht University, 6229 ER Maastricht, The Netherlands
3
Institute of Public Health Genomics, Department of Genetics and Cell Biology, FHML, Maastricht University, 6229 ER Maastricht, The Netherlands
4
Dutch Chlamydia Trachomatis Reference Laboratory, Department of Medical Microbiology, Infectious Diseases and Infection Prevention, Care and Public Health Research Institute (CAPHRI), Maastricht University Medical Centre (MUMC+), 6229 GT Maastricht, The Netherlands
5
Department of Gynecology and Obstetrics, Catharina Hospital Eindhoven, 5623 EJ Eindhoven, The Netherlands
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(9), 3954; https://doi.org/10.3390/ijms26093954
Submission received: 19 March 2025 / Revised: 16 April 2025 / Accepted: 17 April 2025 / Published: 22 April 2025
(This article belongs to the Special Issue Microbiota and Cancer: 4th Edition)

Abstract

Persistent high-risk Human Papillomavirus infection is the primary factor in cervical carcinogenesis. However, other host-related features are believed to play a role as well. Recent research suggests that the vaginal microbiome and the immune microenvironment play a significant role in the acquisition and persistence of Human Papillomavirus infection, as well as in the regression or progression of cervical intraepithelial lesions. Studies in this emerging field describe factors associated with this interaction, though the precise nature remains incompletely understood. In this narrative review, we aim to summarize the current literature on the topic and propose hypotheses and recommendations for future research and treatment strategies.

Graphical Abstract

1. Introduction

Human Papillomavirus (HPV) is a prevalent virus that is primarily transmitted through sexual contact, with a lifetime risk of acquisition of up to 80% [1]. High-risk types of HPV (hrHPV) are oncogenetic [2], and persistent hrHPV infections are causally related to the development of premalignant anogenital intraepithelial neoplasia, including cervical low- and high-grade squamous intraepithelial lesions (cLSIL and cHSIL), and eventually progression into cervical squamous cell carcinoma [1,3,4].
Mounting evidence suggests that both the vaginal microbiome (VMB) and the host immunity play a pivotal role in HPV infection, persistence, and lesion progression. The VMB is thought to influence the host’s immune environment and vice versa [5]. The human VMB can be characterized into five community state types (CST) (Table 1) [6]. Unlike other microbiomes, such as the gut microbiome, the optimal VMB is characterized by low microbial diversity and high abundance of Lactobacillus (L.) species (spp.) as lactobacilli produce lactic acid and bacteriocin, which create a stable VMB by maintaining a low pH environment and creating a barrier against infections [7,8], inhibiting the proliferation of pathogens [9]. Several studies have been conducted to explore the interplay between CSTs and HPV infection. CST I, which is dominated by L. crispatus, is believed to be the most beneficial CST, and epidemiological studies have associated it with a decreased detection of HPV and cHSILs [10]. A greater diversity of bacterial species is associated with vaginal dysbiosis, such as bacterial vaginosis, which positively correlates with the risk of acquiring HPV infection and cervical lesions [11]. Species linked to dysbiosis can increase the vaginal pH [12] and reduce levels of hydrogen peroxide (H2O2) [13]. These alterations can cause disruptions of the mucosal barrier, thereby facilitating the entry of HPV capsids [14]. The mechanisms underlying the interaction between HPV and the VMB are still not fully understood. The host’s immune response within HPV-induced cervical lesions is also believed to play a crucial role in the progression and regression of cervical dysplasia [15]. An imbalance between T-helper 1 (Th1) and T-helper 2 (Th2) cells contributes to persistent hrHPV infection and the development of cervical lesions [16,17].
While current evidence suggests an interplay between HPV, the VMB, and the immune microenvironment in cervical carcinogenesis, the precise nature of these mechanisms remains incompletely understood. Therefore, the aim of this narrative review is to summarize the available literature to explore how the VMB and the immune microenvironment interact in the context of HPV-induced c(H)SILs.

2. Materials and Methods

The literature search was conducted using PubMed and Embase (OVID) and was last updated on 29 January 2025 (Supplementary Material S1). The results were screened by one researcher (H.C.J.S.). We included original research on the influence of the VMB on HPV infections and HPV-induced cervical lesions, as well as reviews on this topic. Additionally, we included original research and reviews on the immune environment in HPV(-induced) lesions and their connection to the VMB. Finally, we included original research and reviews on treatment modalities for cervical lesions affecting the VMB. Conference abstracts were excluded. A total of 313 articles were full-text reviewed, the most relevant findings will be discussed (Figure 1).

3. Results

3.1. The Vaginal Microbiome and Community State Types (CST)

The VMB is a complex community of microorganisms that play a crucial role in maintaining female urogenital health. In previous research, Ravel et al. divided the most common VMB compositions into five CSTs. These communities were grouped according to species abundance. CST I is dominated by L. crispatus, CST II is L. gasseri-dominated, and CST III and V are dominated by L. iners and L. jensenii, respectively. CST IV is considered the most diverse community with the highest pH [6]. CST I has the lowest median pH compared to communities dominated by Lactobacillus spp. other than L. crispatus. Vaginal pH is positively associated with (hr)HPV infection [18,19]. The difference in vaginal pH between CSTs suggests that the production of lactic acid might differ between species within the Lactobacillus genus [6]. In later research, the two isoforms of lactic acid have been studied. L. crispatus produces both the D- and L-isoform of lactic acid, whereas L. iners produces only L-lactic acid [20,21,22]. Vaginal anaerobes, on the other hand, produce cytokines and inflammatory mediators which are associated with chronic inflammation [23], and mucin degrading enzymes [24,25] that are thought to affect the mucosal layer of the cervical epithelium, reducing its ability to act as a barrier against infections [25].
Longitudinal studies have shown that the VMB is relatively stable in the majority of women [26,27,28,29,30]. VMBs dominated by L. crispatus and/or L. gasseri are generally stable, with transitions primarily occurring during menses, after which the microbiome typically transitions back. On the other hand, CST III and IV are less stable, frequently undergoing transitions between one another. These less stable CSTs are less likely to transition to the more optimal CSTs I or II [29]. Women with VMB dominated by L. crispatus are less likely to transition to bacterial vaginosis (BV)-associated VMB than women with L. iners-dominated VMB [29,31,32].

3.2. The Role of the Vaginal Microbiome in HPV-Induced Lesions

As mentioned, the most important etiological factor in cervical carcinogenesis is a persistent infection with hrHPV. However, HPV alone is thought to be insufficient in causing cervical malignancies. Mounting evidence supports the causal link between vaginal dysbiosis and cervical carcinogenesis [33,34]. Research has shown that the diversity of VMB increased with advancing cervical dysplasia severity [35,36,37,38] and that an anaerobic VMB is associated with a lower regression rate of HPV-induced lesions [39].

3.2.1. Lactobacillus Species in the Vaginal Microenvironment

Microorganisms belonging to the phylum Firmicutes, specifically Lactobacillus spp., are most often associated with HPV-negative outcomes [40,41] and normal cytology or histology results [42,43]. Additionally, the abundance of Lactobacillus spp. is negatively correlated with HPV persistence [44] and positively correlated with infection clearance [45]. The protective role of Lactobacillus spp. lies in its diverse functions. Lactobacilli can create a biofilm and a protective barrier by adhering to epithelial surfaces and cervicovaginal mucus, thereby inhibiting the adhesion of pathogens [46,47]. Additionally, antimicrobial compounds such as biosurfactants, H2O2, and lactic acid are produced, helping to prevent HPV from invading cervical epithelial cells [47,48]. For the synthesis of lactic acid, glycogen is essential. An increased production of estrogen leads to an accumulation of glycogen [46], which leads to cervical enrichment of Lactobacillus spp. [49]. A higher Lactobacillus spp. abundance is correlated with a lower pH [50].
The roles of different Lactobacillus spp. in HPV-induced cervical carcinogenesis have been studied extensively. VMB dominated by Lactobacillus spp. is considered to be the most beneficial community, especially Lactobacillus crispatus-dominated communities. It is now well established from a variety of studies that a higher abundance of L. crispatus is associated with (hr)HPV-negative outcomes [43,51,52] at baseline and follow-up. Additionally, it is inversely associated with hrHPV persistence [53] and the abundance of L. crispatus decreases with increasing severity of cervical lesions [50,54] while higher levels of L. crispatus at baseline decrease the risk of developing cSIL [55]. Decreased amounts of L. crispatus have been found in VMB with a higher alpha diversity [50] and patients with (hr)HPV infection [56], LSIL [57], HSIL [43,57,58], and even cervical carcinoma [54,57]. The protective role of L. crispatus can be explained by its higher H2O2 production, which has been observed in L. crispatus-dominated communities [50] and is known to inhibit pathogens. Additionally, as mentioned, L. crispatus produces both the D- and L-isoforms of lactic acid [20,21,22]. Notably, D-lactic acid levels have been found to be significantly higher in VMB containing L. crispatus compared to L. iners [59]. Lower levels of D-lactic acid have been associated with cHSIL and cervical cancer [60]. Taken together, these characteristics indicate that L. crispatus plays a beneficial role in the vaginal microenvironment.
While numerous studies have strongly associated L. crispatus with favorable outcomes, the findings regarding other Lactobacillus spp. are more diverse. Many studies have highlighted the protective role of L. gasseri in preventing cervical carcinogenesis. L. gasseri-dominated VMB (CST II) has been associated with normal cervical cytology [42] and HPV clearance [13,61]. Also, a decrease in the abundance of L. gasseri was observed in HPV-positive women [56]. However, one study reported an increase in L. gasseri in HPV-positive women [62]. As most studies provide evidence for the beneficial role of L. gasseri, while only one study highlights a possible negative effect of this species, it is reasonable to assume that L. gasseri is a beneficial microorganism in protecting against HPV-induced cervical lesions. Furthermore, L. gasseri produces both D- and L-lactic acid, which supports this assumption [60].
The findings concerning the role of L. iners in HPV-induced lesions are more inconsistent. While several studies have shown that a high abundance of L. iners (CST III) is associated with HPV-negative outcomes [43], the absence of cervical abnormalities [42], HPV clearance [63,64], and lower alpha diversity [50], as well as that a decrease in L. iners increases the susceptibility to HPV infection [56,65], HPV persistence [66] and higher alpha diversity [67], other studies have reported contrasting findings. Specifically, L. iners has been linked to (hr)HPV-positivity [68,69], slower infection clearance [13,70], and an increased risk of neoplastic progression [40,71,72,73] including cLSIL [58], cHSIL [74,75], and cervical carcinoma [76,77]. The variety of findings might be caused by the production characteristics of L. iners. On the one hand, L. iners exhibits characteristics typical of lactobacilli, but on the other hand, there are subtle differences. Lower levels of H2O2 have been observed [50], while higher levels of H2O2 are associated with defense against invading pathogens. The D-isoform of lactic acid is believed to play a protective role in cervical carcinogenesis. Research has shown that in L. iners-dominated communities, D-lactic acid levels are decreased, while L-lactic acid levels—and consequently the L/D-lactic acid ratio—are elevated in women with cHSIL and cervical carcinoma [60]. These characteristics contribute to a reduced capacity to maintain an acidic vaginal environment [78] and, as a result, a suboptimal vaginal pH. This in turn increases the risk of anaerobic bacteria and HPV capsids invading the epithelial cells.
While existing evidence on L. jensenii is more limited compared to the previously discussed Lactobacillus spp., contrasting results are also reported in this case. On the one hand, its enrichment is associated with the control—HPV-negative—group [79], while its reduction is linked to cervical lesions [69]; conversely, an increase in L. jensenii has been observed in HPV-positive women [56], in HPV persistence [66], and in cervical lesions [71]. In previous literature, the specific characteristics of L. jensenii have not been fully elucidated. A hypothesis for the increased association of L. jensenii, compared to L. crispatus, with HPV infection and cervical lesions could be that while L. jensenii shares similar characteristics, its production of antimicrobial compounds and its ability to lower the vaginal pH may be less pronounced than those of L. crispatus.

3.2.2. Species Involved in Vaginal Dysbiosis

Genera other than Lactobacillus are generally associated with vaginal dysbiosis. Lactobacillus-depleted communities are considered risk factors for HPV acquisition [80], persistence, and cervical lesion progression [37,41,81]. When Lactobacillus dominance is lost, microbial diversity increases. These diverse vaginal anaerobes produce mucindegrading enzymes, which cause changes in immune and epithelial homeostasis [46]. Vaginal dysbiosis, characterized by higher alpha diversity [82], is typical of CST IV. Numerous species have been linked to a less optimal vaginal environment and an increased risk of HPV infection, and consequently, cervical carcinogenesis. The most important findings will be discussed.
Bacterial vaginosis (BV)-associated pathogens were the first to be studied in relation to HPV and cervical dysplasia. BV is an infection caused by a depletion of lactobacilli and a proliferation of Gardnerella (G.) vaginalis and other anaerobic bacteria and it is positively correlated with hrHPV infection [38,63,83,84] and persistence [85]. BV-related bacteria are likely related to the production of amines, which can induce oxidative stress [47], this oxidative stress is thought to promote the progression of preneoplastic cervical lesions [86]. G. vaginalis can adhere to the vaginal epithelium, providing a framework for the production of biofilms and the proliferation of microorganisms [87,88]. Furthermore, Gardnerella produces sialidases which can degrade mucosa-protecting factors, causing destruction of epithelial cells and bacterial invasion [48]. Usyk et al. showed a positive correlation of G. vaginalis with the progression of the disease [63].
In addition to G. vaginalis, other species within the Actinobacteria phylum are associated with BV and HPV. Fannyhessea (F.) vaginae is observed in most BV cases and is associated with a higher vaginal pH [89]. The presence of any Fannyhessea spp. not only increases the risk of HPV infection but it is also associated with a higher prevalence of cLSIL, cHSIL [89,90], and cervical carcinoma [54]. Atopobium (A.) spp., specifically A. vaginae, are frequently detected in (hr)HPV-positive women [91,92] and cervical lesions [55,72] including cHSIL [57,93].
Another phylum associated with BV is Fusobacteriota, with the genus Sneathia (S.) being most commonly enriched in (hr)HPV-positive samples [94,95] and cHSIL [36]. In a treated cohort, S. amnii was overrepresented before local excision of cervical dysplasia, but no longer overexpressed following treatment. This finding suggests an interaction between S. amnii and the development of cSIL [35]. In another study, an increased abundance of S. sanguinegens was linked to bacterial biofilms in vaginal fluids [96]. Additionally, S. vaginalis can adhere to malignant cervical epithelial cells [97], suggesting a potential influence of S. vaginalis on the cervical microenvironment.
Prevotella (P.) spp., belonging to the Bacteroidetes phylum, are associated with both BV and HPV as well [48,82]. P. bivia is considered an early colonizer in BV, it is believed that P. bivia paves the way for secondary colonizers, such as previously mentioned Atopobium and Sneathia [47]. P. timonensis is inversely associated with lesion regression [39] and positively correlated to cHSIL [56], while P. amnii is more commonly found in cLSIL [56]. Like Gardnerella, Prevotella spp. secrete sialidases which can contribute to HPV persistence [98]. With the presence of Prevotella spp., the diversity of cervicovaginal flora increases and Lactobacillus abundance decreases [36,49].
To conclude, BV-associated bacteria are commonly enriched in HPV-positive patients [95] and are associated with a slower infection clearance rate [13] and HPV persistence [94]. These bacteria are negatively correlated with the presence of L. crispatus, yet exhibit symbiotic relationships with each other [54,99,100].
While extensive research has been conducted on the role of BV-associated bacteria in HPV-induced lesions, other bacteria are associated with CST IV, and vaginal dysbiosis, as well. The most commonly described genera within the Firmicutes phylum are Streptococcus, Mycoplasma, Shuttleworthia, and Dialister. These have been associated with (hr)HPV positivity [52,56,101,102], infection persistence [100], cLSIL [36], cHSIL [56,74,103], and cervical carcinoma [36,49,54]. G. vaginalis primarily drives peptidoglycan biosynthesis. However, Streptococcus spp. contribute to this process [90]. Peptidoglycan biosynthesis has been linked to the development of cervical cancer [104], likely because peptidoglycan can be recognized by the immune system as a sign of bacterial infection. This can trigger inflammation, and chronic inflammation is a known risk factor for the development of malignant lesions.
Pseudomonas spp., within the Proteobacteria phylum, have been found in communities of women infected with (hr)HPV [49]. Persistent infection [100,105] and ensuing cervical lesions [43,106], including cHSIL [103], have been linked to this bacterium. However, another study found a decrease in Pseudomonas spp. as the severity of lesions progressed [107].
The Tenericutes phylum has been associated with HPV-positive outcomes. Specifically, Ureaplasma (U.) spp. are linked to hrHPV infections [92,101,108,109] and cervical dysplasia [110]. In contrast, U. urealyticum has been positively correlated with infection clearance [51].
Trichomonas (T.) vaginalis, a species within the Metamonada phylum, is positively correlated with hrHPV infection and an increased risk of cervical dysplasia development [111]. This association may be explained by Trichomonas competing with lactobacilli for glycogen in vaginal epithelial cells, which inhibits the growth of Lactobacillus spp. and leads to an increased vaginal pH [112].
Research showed a positive association between HPV infection, cSIL, and Chlamydia (C.) trachomatis [34,38,49,113]. This increased chance of HPV acquisition is likely a consequence of the disruption in the cervical epithelium caused by C. trachomatis, increasing the chance of HPV entry to the basal epithelium [114,115,116,117].
In summary, bacteria that characterize the diversity of CST IV are significantly associated with (hr)HPV infection, persistence, and progression to cervical dysplasia and even cervical carcinoma. CST IV is generally linked to a higher vaginal pH, which increases the susceptibility to pathogen invasion and decreases Lactobacillus spp. dominance. No significant differences in the VMB composition immediately prior to and immediately after regression of CIN 2 were observed, suggesting that cervical dysplasia may not be driving the VMB but that the VMB itself could be a risk factor for the development of cSIL [39]. While HPV has been shown to influence the composition and diversity of the VMB, BV-associated bacteria can further reinforce this trend [107]. In contrast, some CST IV-related bacteria have also been found in HPV-negative cases and HPV clearance [51,107], suggesting that the relationship between CST IV and HPV infection is not straightforward. This implies that other factors, such as the immune microenvironment, play a role in this interplay.

3.3. The Immune Microenvironment in HPV-Induced Lesions

HPV infection can alter the host immune response [118], disrupting both innate and adaptive immunity, leading to persistent infection and cSIL development [119]. HPV-induced changes in immunity could potentially create an environment that facilitates the growth of pathogenic microorganisms, further driving inflammation and establishing a positive feedback loop [46,120], which ultimately promotes the development of cervical lesions [120].
B and T lymphocytes are key elements in the anti-tumor immune response. T lymphocyte-mediated cellular immunity can inhibit the growth of tumor cells [121,122,123]. The anti-tumoral characteristics of T cells consist of CD4+ T helper cells and CD8+ cytotoxic T cells. A decrease in the CD4+/CD8+ ratio indicates that the immune response is impaired [124,125]. Wang, et al. observed that the systemic CD4+ T cell count and CD4+/CD8+ ratio of patients infected with hrHPV were significantly lower compared to the control group [126]. Th1 cells can activate cellular immunity and release pro-inflammatory cytokines including interferon-gamma (IFN-γ), interleukin (IL)-1β, IL-2, IL-6, IL-8, tumor necrosis factor (TNF)-α, and TNF-β. IL-1β is associated with tumorigenesis, angiogenesis, metastasis, and an increased risk of progression to cervical carcinoma in women with cHSIL [78]. IL-6 is believed to promote cell proliferation and inhibit apoptosis. High levels of IL-6 could stimulate Vascular Endothelial Growth Factor (VEGF) production and promote cervical carcinogenesis [127]. IL-8 is crucial in transporting immune cells to the inflammation site [78]. Th2 cells regulate humoral immunity, and regulatory T cells (Tregs) are important in immunosuppression. Both produce anti-inflammatory cytokines IL-4 and IL-10. IL-4 maintains tissue health by regulating the immune response and indirectly impacting the microbial community composition [78]. CD4+ T cells can differentiate into Th17 cells, which produce IL-17. IL-17 promotes inflammation, which can suppress the effectiveness of the immune response, potentially leading to an ineffective defense against HPV [128].
As reviewed by Muntinga et al., the host’s immunity within HPV-induced cervical lesions plays a crucial role in the progression and regression of cervical dysplasia [15]. In cHSIL, there is an increase in immature dendritic cells (iDCs), Tregs, programmed death-ligand (PD-L1+) cells, and macrophages, while the levels of Langerhans cells (LCs), CD4+, and CD8+ T cells decrease compared to both healthy cervix and low-grade lesions [15]. In women with (pre)malignant cervical lesions, lower serum concentrations of IFN-γ and higher serum concentrations of IL-10 were found. Thus, suggesting that an imbalance between Th1 and Th2 cells may lead to persistent HPV infection and lesion progression [16,17]. In another study, the Th1/Th2 ratio in cervicovaginal lavages was decreased [129]. As the severity of cervical lesions increased, concentrations of IL-10, SIgA, and IgG were elevated, while IL-2 levels were decreased in cervicovaginal lavages [129]. In patients with HPV clearance, more endocervical LCs were observed than in persistence and HPV-negative controls [130].

3.4. The Interplay Between the Vaginal Microbiome and the Immune Microenvironment in HPV-Induced Lesions

As previously mentioned, vaginal dysbiosis can influence the host’s immune response and cause disruption of the defense barriers, thereby causing chronic infection and the release of pro-inflammatory cytokines which can ultimately lead to cervical (pre)malignant lesions [37].
In addition to Lactobacillus’ ability to maintain the acidic environment and low vaginal pH, it can produce metabolites and stimulate immune cells to release cytokines, thereby enhancing the host’s anti-infective response [131]. In VMB depleted of lactobacilli, the vaginal immune barrier is compromised, allowing HPV and other pathogenic microorganisms to adhere. This vaginal dysbiosis leads to a decrease in an effective cervical immune response while simultaneously promoting the colonization of abnormal vaginal flora [132]. VMB characterized by an abnormal pH, vaginal dysbiosis, and Lactobacillus-depletion showed elevated immune markers in vaginal lavages [41]. An increase in pro-inflammatory cytokines, IL-1β, IL-15, and TNF-α was observed. As well as an increase in regulatory cytokine IL-12, and growth factor FGF2 [41]. Transient inflammation is likely essential for clearance, but the presence of both pro-inflammatory and anti-inflammatory cytokines is indicative of chronic infection [47]. In another study, Lactobacillus spp. were negatively correlated with Th2 cytokine expression (IL-5, IL-13) and positively correlated with Th1 cytokine expression (IL-2 and IL-12) in cervicovaginal secretions [133]. IL-2 and IL-12 play a role in the survival and activation of T lymphocytes [134]. However, the various Lactobacillus spp. can differ in their immunoregulatory functions. For instance, L. gasseri (CST II) is associated with increased levels of IFN-γ and decreased levels of IL-17 in peripheral blood, whereas L. iners-dominance (CST III) is linked to optimal levels of both cytokines. IL-17 is produced by Th17 cells, which are a subtype of CD4+ T cells [128]. Remarkably, G. vaginalis (CST IV) is associated with elevated levels of IL-17 and reduced levels of IL-10 and IFN-γ in peripheral blood compared to Lactobacillus-dominated VMB. This negative correlation between IL-17 and IFN-γ suggests that bacteria associated with vaginal dysbiosis compromise the Th1 response by promoting the differentiation of Th17 cells and increasing IL-17 concentrations in the immune environment, thereby creating an ineffective antiviral immune response [128]. The presence of Gardnerella was positively correlated with Th2 cytokine expression and negatively correlated with Th1 cytokine expression in cervicovaginal secretions [133]. Additionally, enhanced levels of Toll like receptor (TLR) 7 and TLR 9 were found in HPV-infected cervical cells of BV-positive women [91]. Activation of TLRs leads to the production of IFNs and inflammatory cytokines. However, prolonged TLR activation might cause tissue damage [91]. Di Paola et al. associated Prevotella (CST IV) with HPV infection and persistence [94]. It can modulate the host’s mucosal immunity by increasing the number of cytokines, e.g., Th2-induced IL-5, in cervicovaginal samples [135] and by secreting proteases that degrade host antibodies and transfer ammonia to Gardnerella [136]. Additionally, Prevotella is positively correlated with IP-10 [137]. Chemokine IP-10 is an IFN-γ-induced protein involved in transporting immune cells to inflammatory sites [138]. Lactobacillus, on the other hand, inhibits IP-10 secretion and reduces the inflammatory response [139,140]. In VMB dominated by BV-associated bacteria, levels of IL-1β and TNF-α are increased in cervical secretions, which is associated with an increased risk of lesion progression [141]. F. vaginae (CST IV) is able to activate TLR 2 and NF-κβ in cervicovaginal epithelial cells, thereby triggering the production of inflammatory cytokines and Th1 IFNs, initiating an innate immune response [142,143]. Persistent activation of inflammatory factors can lead to chronic inflammation, which in turn facilitates the entry of HPV capsids and the development of cervical dysplasia [37].
Other than BV-associated bacteria, it is known that C. trachomatis (CST IV) can adhere to the genital mucosa and disrupt the epithelial barrier, thereby causing an inflammatory reaction and increasing the vaginal pH, which has a detrimental effect on cervicovaginal immunity and facilitates the invasion of other pathogenic microorganisms. This increases the risk of a persistent HPV infection [144].
Atopobiaceae (CST IV) were enriched in cLSIL, cHSIL, and cervical carcinoma and positively correlated with IL-1α, IL-4, IL-10, IL-12, IL-36γ, IFN-α2, IFN-γ, and TNF-α in cervicovaginal lavages. Atopobiaceae were negatively correlated with IP-10 and CCL20 [89]. CCL20, also known as MIP-3α, is a chemokine involved in attracting immune cells to the inflammation site [145].
Fusobacterium spp. (CST IV) were associated with higher levels of cervical IL-4 and TGF-β1 [40].
In conclusion, lactobacilli enhance pro-inflammatory immunity by promoting Th1 cytokine expression and decreasing Th2 cytokine expression [133]. These characteristics are typical of transient infections, while a higher alpha diversity and abundance of BV- and CST IV-associated bacteria contribute to chronic infection by increasing pro-inflammatory and anti-inflammatory cytokines in the cervicovaginal environment. As reviewed by Muntinga et al., cervical intralesional immunity is believed to play a role in protecting against HPV infections as well [15]. However, current literature mostly describes changes in immune factors within the cervicovaginal space, and the precise interplay between the VMB, vaginal immunity, and cervical immunity remains unclear. It is plausible that altering the VMB to a more optimal, Lactobacillus-dominant environment could help in creating an effective immune response to clear HPV infections and promote cervical lesion regression.

3.5. Influence of Treatments for cHSIL on the Vaginal Microbiome and Immunological Response

The treatment of cervical intraepithelial neoplasia (CIN) depends on the severity of the lesion. cLSILs spontaneously regress in 60% of patients [146] and expectant management is preferred. In contrast, cHSILs have lower regression rates and more often necessitate treatment. Expectant management may be considered for women under 30 years with CIN 2, as 55% of cases regress spontaneously [146]. Patients with CIN 3 generally need treatment as only 28% spontaneously regress [146]. The most common treatment is a large loop excision of the transformation zone (LLETZ) [147]. While it is effective in up to 90% of patients, complications such as hemorrhage and an almost doubled risk of premature birth occur [147,148,149]. Therefore, alternative treatment strategies are warranted. Imiquimod, a topical immunomodulatory cream that stimulates the immune response by binding to Toll-like receptors (TLRs) 7 and 8 on immune cells, has been studied as an alternative treatment option. However, response rates vary between 52% and 73% [150,151,152]. In this section, we summarize current knowledge on the effects of different treatments on VMB composition and host immunity in HPV infection and outline future directions for alternative therapies in cSILs.

3.5.1. Effects of LLETZ on VMB and Immunity

Across different populations, LLETZ resulted in shifts towards a Lactobacillus-dominant VMB. Zhang, et al. observed a transition from CST IV (Prevotella spp. and Sneathia spp.) to CST III (L. iners) 3 months post-LLETZ (n = 26) [153]. This transition occurred simultaneously with hrHPV clearance. Similarly, Giovannetti et al. found a significant decrease in CST IV-related Streptococcus and Prevotella 3 months post-LLETZ, with U. parvum and Streptococcus spp. remaining significantly reduced after 6 months (n = 23) [154]. While Wiik et al. and Zhang et al. reported increased Lactobacillus spp. abundance at 3 and 6 months [153,155], no significant changes were found at 12 months [155]. Caselli et al. (n = 85) found a significant increase in L. crispatus (CST I) and a decrease in CST IV bacteria at least 6 months post-LLETZ in patients who cleared hrHPV, whereas those with persistent hrHPV infection showed no significant changes in VMB composition [156]. Similarly, Kawahara et al. (n = 41) found a decrease in Atopobium spp. (CST IV) in patients who cleared HPV post-LLETZ [157].
To our knowledge, there are few studies investigating the interplay between the VMB and the immune microenvironment in HPV-induced lesions pre- and post-treatment. Pro-inflammatory cytokines (e.g., IL-1α, IL-1β, IL-6, IL-8, TNF-α) in the vaginal environment were significantly reduced post-LLETZ in HPV-cleared patients. These levels remained higher in patients with HPV persistence [156,157].

3.5.2. Lactobacillus as Probiotics

Many strategies have been suggested to improve the VMB, the most well investigated being probiotics. Given its role in promoting a healthy VMB, L. crispatus may have a potential in cSIL treatment. Oral administration of L. crispatus M247 in 24 CST IV patients with HPV infection resulted in L. crispatus dominance in 23 patients post-treatment with only 20% of these patients being HPV-positive [158]. Dellino et al. (n = 160) showed that HPV-positive patients with cLSIL treated with oral L. crispatus M247 during 12 months, showed higher lesion regression rates and HPV clearance compared to the HPV-positive control group [159]. In 50 hrHPV-positive patients, intravaginal transplantation of L. crispatus led to a significant increase in HPV clearance and restoration of Lactobacillus abundance after 6 months compared to the control group [160].

3.5.3. Immunomodulatory Treatment

While the use of probiotics is an emerging field, no studies have investigated the effects of immunomodulatory treatment, including imiquimod, on the VMB. Previous research has shown that imiquimod induces a strong influx of intraepithelial and stromal CD4+ T cells in patients who responded to imiquimod treatment for cHSIL, but not in non-responders. It is believed that a ‘hot’, pro-inflammatory, cervical immune microenvironment is necessary for a complete response to imiquimod therapy [15,161]. However, its relationship with the VMB remains unknown.
In conclusion, previous research indicates that LLETZ generally promotes a shift towards a healthier, Lactobacillus-dominant VMB, and a reduction in vaginal inflammation, coinciding with HPV clearance. In patients with HPV persistence, however, the reverse is seen with the persistence of dysbiosis, chronic vaginal inflammation, and a dysfunctional systemic immunity against HPV. Probiotics aid in restoring a healthy VMB, resulting in improved HPV clearance in cLSIL, however little is known of its effect in the treatment of cHSIL. Imiquimod can be used as a noninvasive treatment of cHSIL, however, a pre-existing functional cervical microenvironment seems necessary for lesions to regress. It could be hypothesized that treatment of vaginal dysbiosis could result in restoration of a more functional cervical immunity, facilitating response to imiquimod.

4. Discussion

In this narrative review, we summarize current literature on the interplay between the vaginal microbiome and the immune microenvironment in cervical carcinogenesis. Research has shown that a Lactobacillus-dominated VMB is beneficial, with L. crispatus (CST I) being the optimal community, as it is most commonly associated with HPV-negative outcomes [43,51,52], HPV clearance [53], and cervical lesion regression [55]. This protective state is likely related to Lactobacillus’ ability to maintain an acidic environment and preserve the mucosal barrier, preventing pathogens from invading epithelial cells [131]. Additionally, lactobacilli can produce metabolites and stimulate immune cells to release pro-inflammatory cytokines such as IL-1β and TNF-α [41]. Vaginal dysbiosis, characterized by greater diversity, is associated with higher susceptibility to HPV infection and persistence [51], as well as an increased risk of cervical dysplasia [103], with diversity rising as lesions progress [50,162]. Increasing diversity is associated with higher levels of inflammatory cytokines [78], indicative of a chronic inflammatory status impairing host immunity [109].
HPV capsids are able to modulate the host’s immune response by upregulating TLR activation and cytokine production. However, additional factors are required to drive cervical dysplasia progression. Next to HPV’s immune-evading strategies, vaginal dysbiosis can lead to changes in the host’s immune response, further altering the cervicovaginal environment and contributing to cervical carcinogenesis [78].
LLETZ has been associated with a shift towards a Lactobacillus-dominant VMB in HPV-cleared patients. In contrast, HPV persistence post-LLETZ is related to vaginal dysbiosis and chronic inflammation [153,154,155,156,157]. While probiotics have been shown to alter the VMB to a more optimal state in cLSIL [158,159,160], its effects in cHSIL remain unexplored. Imiquimod is a noninvasive, alternative treatment strategy for cHSIL. However, a pre-existing functional cervical immune microenvironment appears to be crucial for a complete response [161]. Restoring vaginal dysbiosis, and consequently promoting a more balanced cervical immune state, could enhance the efficacy of imiquimod therapy in cHSIL patients.
As study selection and screening were performed by a single reviewer, this may have introduced a degree of selection bias, which should be considered when interpreting the findings.

5. Conclusions

To conclude, the VMB plays a pivotal role in the acquisition and persistence of hrHPV infection and cervical carcinogenesis. An optimal VMB is characterized by a high abundance of Lactobacillus spp., particularly L. crispatus, and low microbial diversity. This is associated with HPV-negative outcomes and a healthy cervix. In contrast, communities dominated by anaerobic bacteria, with high diversity, are detrimental to cervical health. Especially BV-associated bacteria are linked to a higher risk of HPV acquisition and progression of cervical lesions. While Lactobacillus spp. promote the production of cytokines associated with transient infections, bacteria linked to vaginal dysbiosis produce high levels of cytokines associated with chronic inflammation, increasing the risk of progression to cervical carcinoma. Understanding the interplay between the VMB and immune responses may be key to developing signatures that can aid in predicting treatment response and developing new treatment strategies.

6. Future Directions

To reduce the need for invasive diagnostics and treatments in HPV-positive patients, identifying biomarkers, microbial and/or immunological, is essential to determine which women are likely to experience spontaneous regression and which will not. Moreover, the identification of biomarkers will aid in identifying new therapeutic strategies targeting the VMB, the immunity, or both, to ensure that women receive the most appropriate therapy for their individual status and to avoid unnecessary LLETZ procedures, associated with risks of preterm birth.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms26093954/s1.

Author Contributions

Conceptualization, H.C.J.S., L.M.S.S., S.A.M., E.M.G.v.E. and P.J.d.V.v.S.; methodology, H.C.J.S. and L.M.S.S.; investigation, H.C.J.S. and L.M.S.S.; data curation, H.C.J.S. and L.M.S.S.; writing—original draft preparation, H.C.J.S.; writing—review and editing, H.C.J.S., L.M.S.S., S.A.M., E.M.G.v.E. and P.J.d.V.v.S.; visualization, H.C.J.S.; supervision, P.J.d.V.v.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Acknowledgments

Servaas A Morré is also affiliated with the Department of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Sam Higginbottom University of Agriculture, Technology and Sciences, Allahabad, UP, India.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
BVBacterial vaginosis
CINCervical intraepithelial neoplasia
cHSILCervical high-grade squamous intraepithelial lesion
cLSILCervical low-grade squamous intraepithelial lesion
cSILCervical squamous intraepithelial lesion
CSTCommunity state type
HPVHuman Papillomavirus
hrHPVHigh-risk Human Papillomavirus
LLETZLarge loop excision of the transformation zone
VMBVaginal microbiome

References

  1. Koutsky, L. Epidemiology of genital human papillomavirus infection. Am. J. Med. 1997, 102, 3–8. [Google Scholar] [CrossRef] [PubMed]
  2. Stanley, M. Pathology and epidemiology of HPV infection in females. Gynecol. Oncol. 2010, 117, S5–S10. [Google Scholar] [CrossRef] [PubMed]
  3. Ho, G.Y.; Bierman, R.; Beardsley, L.; Chang, C.J.; Burk, R.D. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 1998, 338, 423–428. [Google Scholar] [CrossRef] [PubMed]
  4. Baseman, J.G.; Koutsky, L.A. The epidemiology of human papillomavirus infections. J. Clin. Virol. 2005, 32 (Suppl. 1), S16–S24. [Google Scholar] [CrossRef]
  5. Al-Nasiry, S.; Ambrosino, E.; Schlaepfer, M.; Morré, S.A.; Wieten, L.; Voncken, J.W.; Spinelli, M.; Mueller, M.; Kramer, B.W. The Interplay Between Reproductive Tract Microbiota and Immunological System in Human Reproduction. Front. Immunol. 2020, 11, 378. [Google Scholar] [CrossRef]
  6. Ravel, J.; Gajer, P.; Abdo, Z.; Schneider, G.M.; Koenig, S.S.; McCulle, S.L.; Karlebach, S.; Gorle, R.; Russell, J.; Tacket, C.O.; et al. Vaginal microbiome of reproductive-age women. Proc. Natl. Acad. Sci. USA 2011, 108 (Suppl. 1), 4680–4687. [Google Scholar] [CrossRef]
  7. Wilson, W.A.; Roach, P.J.; Montero, M.; Baroja-Fernández, E.; Muñoz, F.J.; Eydallin, G.; Viale, A.M.; Pozueta-Romero, J. Regulation of glycogen metabolism in yeast and bacteria. FEMS Microbiol. Rev. 2010, 34, 952–985. [Google Scholar] [CrossRef]
  8. Zacharof, M.P.; Lovitt, R.W. Bacteriocins Produced by Lactic Acid Bacteria a Review Article. APCBEE Procedia 2012, 2, 50–56. [Google Scholar] [CrossRef]
  9. McMillan, A.; Dell, M.; Zellar, M.P.; Cribby, S.; Martz, S.; Hong, E.; Fu, J.; Abbas, A.; Dang, T.; Miller, W.; et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf. B Biointerfaces 2011, 86, 58–64. [Google Scholar] [CrossRef]
  10. Łaniewski, P.; Cui, H.; Roe, D.J.; Chase, D.M.; Herbst-Kralovetz, M.M. Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment. npj Precis. Oncol. 2020, 4, 22. [Google Scholar] [CrossRef]
  11. Gillet, E.; Meys, J.F.; Verstraelen, H.; Bosire, C.; De Sutter, P.; Temmerman, M.; Broeck, D.V. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: A meta-analysis. BMC Infect. Dis. 2011, 11, 10. [Google Scholar] [CrossRef] [PubMed]
  12. Łaniewski, P.; Barnes, D.; Goulder, A.; Cui, H.; Roe, D.J.; Chase, D.M.; Herbst-Kralovetz, M.M. Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women. Sci. Rep. 2018, 8, 7593. [Google Scholar] [CrossRef] [PubMed]
  13. Brotman, R.M.; Shardell, M.D.; Gajer, P.; Tracy, J.K.; Zenilman, J.M.; Ravel, J.; Gravitt, P.E. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J. Infect. Dis. 2014, 210, 1723–1733. [Google Scholar] [CrossRef]
  14. Schwabe, R.F.; Jobin, C. The microbiome and cancer. Nat. Rev. Cancer 2013, 13, 800–812. [Google Scholar] [CrossRef]
  15. Muntinga, C.L.P.; de Vos van Steenwijk, P.J.; Bekkers, R.L.M.; van Esch, E.M.G. Importance of the Immune Microenvironment in the Spontaneous Regression of Cervical Squamous Intraepithelial Lesions (cSIL) and Implications for Immunotherapy. J. Clin. Med. 2022, 11, 1432. [Google Scholar] [CrossRef]
  16. Fernandes, J.V.; TA, D.E.M.F.; JC, D.E.A.; Cobucci, R.N.; MG, D.E.C.; Andrade, V.S.; JM, D.E.A. Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). Oncol. Lett. 2015, 9, 1015–1026. [Google Scholar] [CrossRef]
  17. Lin, W.; Niu, Z.; Zhang, H.; Kong, Y.; Wang, Z.; Yang, X.; Yuan, F. Imbalance of Th1/Th2 and Th17/Treg during the development of uterine cervical cancer. Int. J. Clin. Exp. Pathol. 2019, 12, 3604–3612. [Google Scholar]
  18. Clarke, M.A.; Rodriguez, A.C.; Gage, J.C.; Herrero, R.; Hildesheim, A.; Wacholder, S.; Burk, R.; Schiffman, M. A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. BMC Infect. Dis. 2012, 12, 33. [Google Scholar] [CrossRef]
  19. Liu, Y.; Li, Z. Vaginal pH value can affect the susceptibility to human papillomavirus infection. BMC Infect. Dis. 2024, 24, 176. [Google Scholar] [CrossRef]
  20. Nunn, K.L.; Wang, Y.Y.; Harit, D.; Humphrys, M.S.; Ma, B.; Cone, R.; Ravel, J.; Lai, S.K. Enhanced Trapping of HIV-1 by Human Cervicovaginal Mucus Is Associated with Lactobacillus crispatus-Dominant Microbiota. mBio 2015, 6, e01084-15. [Google Scholar] [CrossRef]
  21. Witkin, S.S. The vaginal microbiome, vaginal anti-microbial defence mechanisms and the clinical challenge of reducing infection-related preterm birth. BJOG 2015, 122, 213–218. [Google Scholar] [CrossRef] [PubMed]
  22. Reimers, L.L.; Mehta, S.D.; Massad, L.S.; Burk, R.D.; Xie, X.; Ravel, J.; Cohen, M.H.; Palefsky, J.M.; Weber, K.M.; Xue, X.; et al. The Cervicovaginal Microbiota and Its Associations With Human Papillomavirus Detection in HIV-Infected and HIV-Uninfected Women. J. Infect. Dis. 2016, 214, 1361–1369. [Google Scholar] [CrossRef]
  23. Boyle, D.C.; Barton, S.E.; Uthayakumar, S.; Hay, P.E.; Pollock, J.W.; Steer, P.J.; Smith, J.R. Is bacterial vaginosis associated with cervical intraepithelial neoplasia? Int. J. Gynecol. Cancer 2003, 13, 159–163. [Google Scholar] [CrossRef] [PubMed]
  24. Olmsted, S.S.; Meyn, L.A.; Rohan, L.C.; Hillier, S.L. Glycosidase and proteinase activity of anaerobic gram-negative bacteria isolated from women with bacterial vaginosis. Sex. Transm. Dis. 2003, 30, 257–261. [Google Scholar] [CrossRef] [PubMed]
  25. Lamont, R.F.; Sobel, J.D.; Akins, R.A.; Hassan, S.S.; Chaiworapongsa, T.; Kusanovic, J.P.; Romero, R. The vaginal microbiome: New information about genital tract flora using molecular based techniques. BJOG 2011, 118, 533–549. [Google Scholar] [CrossRef]
  26. Wertz, J.; Isaacs-Cosgrove, N.; Holzman, C.; Marsh, T.L. Temporal Shifts in Microbial Communities in Nonpregnant African-American Women with and without Bacterial Vaginosis. Interdiscip. Perspect. Infect. Dis. 2008, 2008, 181253. [Google Scholar] [CrossRef]
  27. Biagi, E.; Vitali, B.; Pugliese, C.; Candela, M.; Donders, G.G.; Brigidi, P. Quantitative variations in the vaginal bacterial population associated with asymptomatic infections: A real-time polymerase chain reaction study. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28, 281–285. [Google Scholar] [CrossRef]
  28. Santiago, G.L.; Cools, P.; Verstraelen, H.; Trog, M.; Missine, G.; El Aila, N.; Verhelst, R.; Tency, I.; Claeys, G.; Temmerman, M.; et al. Longitudinal study of the dynamics of vaginal microflora during two consecutive menstrual cycles. PLoS ONE 2011, 6, e28180. [Google Scholar] [CrossRef]
  29. Gajer, P.; Brotman, R.M.; Bai, G.; Sakamoto, J.; Schütte, U.M.; Zhong, X.; Koenig, S.S.; Fu, L.; Ma, Z.S.; Zhou, X.; et al. Temporal dynamics of the human vaginal microbiota. Sci. Transl. Med. 2012, 4, 132ra152. [Google Scholar] [CrossRef]
  30. Jespers, V.; Menten, J.; Smet, H.; Poradosú, S.; Abdellati, S.; Verhelst, R.; Hardy, L.; Buvé, A.; Crucitti, T. Quantification of bacterial species of the vaginal microbiome in different groups of women, using nucleic acid amplification tests. BMC Microbiol. 2012, 12, 83. [Google Scholar] [CrossRef]
  31. Mitchell, C.; Moreira, C.; Fredricks, D.; Paul, K.; Caliendo, A.M.; Kurpewski, J.; Ingersoll, J.; Cu-Uvin, S. Detection of fastidious vaginal bacteria in women with HIV infection and bacterial vaginosis. Infect. Dis. Obstet. Gynecol. 2009, 2009, 236919. [Google Scholar] [CrossRef] [PubMed]
  32. Verstraelen, H.; Verhelst, R.; Claeys, G.; De Backer, E.; Temmerman, M.; Vaneechoutte, M. Longitudinal analysis of the vaginal microflora in pregnancy suggests that L. crispatus promotes the stability of the normal vaginal microflora and that L. gasseri and/or L. iners are more conducive to the occurrence of abnormal vaginal microflora. BMC Microbiol. 2009, 9, 116. [Google Scholar] [CrossRef] [PubMed]
  33. Brusselaers, N.; Shrestha, S.; van de Wijgert, J.; Verstraelen, H. Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: Systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2019, 221, 9–18.e8. [Google Scholar] [CrossRef]
  34. Bowden, S.J.; Doulgeraki, T.; Bouras, E.; Markozannes, G.; Athanasiou, A.; Grout-Smith, H.; Kechagias, K.S.; Ellis, L.B.; Zuber, V.; Chadeau-Hyam, M.; et al. Risk factors for human papillomavirus infection, cervical intraepithelial neoplasia and cervical cancer: An umbrella review and follow-up Mendelian randomisation studies. BMC Med. 2023, 21, 274. [Google Scholar] [CrossRef]
  35. Mitra, A.; MacIntyre, D.A.; Paraskevaidi, M.; Moscicki, A.B.; Mahajan, V.; Smith, A.; Lee, Y.S.; Lyons, D.; Paraskevaidis, E.; Marchesi, J.R.; et al. The vaginal microbiota and innate immunity after local excisional treatment for cervical intraepithelial neoplasia. Genome Med. 2021, 13, 176. [Google Scholar] [CrossRef]
  36. Wu, S.; Ding, X.; Kong, Y.; Acharya, S.; Wu, H.; Huang, C.; Liang, Y.; Nong, X.; Chen, H. The feature of cervical microbiota associated with the progression of cervical cancer among reproductive females. Gynecol. Oncol. 2021, 163, 348–357. [Google Scholar] [CrossRef]
  37. Li, X.; Wu, J.; Wu, Y.; Duan, Z.; Luo, M.; Li, L.; Li, S.; Jia, Y. Imbalance of Vaginal Microbiota and Immunity: Two Main Accomplices of Cervical Cancer in Chinese Women. Int. J. Womens Health 2023, 15, 987–1002. [Google Scholar] [CrossRef]
  38. Yang, J.; Long, X.; Li, S.; Zhou, M.; Hu, L.N. The correlation between vaginal pathogens and high-risk human papilloma virus infection: A meta-analysis of case-control studies. Front. Oncol. 2024, 14, 1423118. [Google Scholar] [CrossRef]
  39. Mitra, A.; MacIntyre, D.A.; Ntritsos, G.; Smith, A.; Tsilidis, K.K.; Marchesi, J.R.; Bennett, P.R.; Moscicki, A.B.; Kyrgiou, M. The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions. Nat. Commun. 2020, 11, 1999. [Google Scholar] [CrossRef]
  40. Audirac-Chalifour, A.; Torres-Poveda, K.; Bahena-Román, M.; Téllez-Sosa, J.; Martínez-Barnetche, J.; Cortina-Ceballos, B.; López-Estrada, G.; Delgado-Romero, K.; Burguete-García, A.I.; Cantú, D.; et al. Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study. PLoS ONE 2016, 11, e0153274. [Google Scholar] [CrossRef]
  41. Łaniewski, P.; Joe, T.R.; Jimenez, N.R.; Eddie, T.L.; Bordeaux, S.J.; Quiroz, V.; Peace, D.J.; Cui, H.; Roe, D.J.; Caporaso, J.G.; et al. Viewing Native American Cervical Cancer Disparities through the Lens of the Vaginal Microbiome: A Pilot Study. Cancer Prev. Res. 2024, 17, 525–538. [Google Scholar] [CrossRef] [PubMed]
  42. McKee, K.S.; Carter, K.A.; Bassis, C.; Young, V.B.; Reed, B.; Harper, D.M.; Ruffin, M.T.t.; Bell, J.D. The vaginal microbiota, high-risk human papillomavirus infection, and cervical cytology: Results from a population-based study. Gynecol. Pelvic Med. 2020, 3, 18. [Google Scholar] [CrossRef] [PubMed]
  43. Huang, X.; Li, C.; Li, F.; Zhao, J.; Wan, X.; Wang, K. Cervicovaginal microbiota composition correlates with the acquisition of high-risk human papillomavirus types. Int. J. Cancer 2018, 143, 621–634. [Google Scholar] [CrossRef] [PubMed]
  44. Avsaroglu, E.; Kaleli, B.; Kilic, D.; Kaleli, I.; Guler, T. A Decrease in Lactobacilli in the Vaginal Microbiota Is Independently Associated With HPV Persistence in Women With High-Risk HPV Infection. Cureus 2023, 15, e50907. [Google Scholar] [CrossRef]
  45. Nanaiah, S.P.; Rudresh, S.M.; Ramaiah, R. Role of Host Cervicovaginal Microbiota in Persistence of High-Risk HPV Infection in Women Attending Gynecology Outpatient Department in a Tertiary Hospital. Indian J. Gynecol. Oncol. 2023, 21, 1–7. [Google Scholar] [CrossRef]
  46. Torcia, M.G. Interplay among Vaginal Microbiome, Immune Response and Sexually Transmitted Viral Infections. Int. J. Mol. Sci. 2019, 20, 266. [Google Scholar] [CrossRef]
  47. Kyrgiou, M.; Moscicki, A.B. Vaginal microbiome and cervical cancer. Semin. Cancer Biol. 2022, 86, 189–198. [Google Scholar] [CrossRef]
  48. Lin, W.; Zhang, Q.; Chen, Y.; Dong, B.; Xue, H.; Lei, H.; Lu, Y.; Wei, X.; Sun, P. Changes of the vaginal microbiota in HPV infection and cervical intraepithelial neoplasia: A cross-sectional analysis. Sci. Rep. 2022, 12, 2812. [Google Scholar] [CrossRef]
  49. Liu, H.; Liang, H.; Li, D.; Wang, M.; Li, Y. Association of Cervical Dysbacteriosis, HPV Oncogene Expression, and Cervical Lesion Progression. Microbiol. Spectr. 2022, 10, e0015122. [Google Scholar] [CrossRef]
  50. Cheng, L.; Yan, C.; Yang, Y.; Hong, F.; Du, J. Exploring the Clinical Signatures of Cervical Dysplasia Patients and Their Association With Vaginal Microbiota. Cancer Med. 2024, 13, e70440. [Google Scholar] [CrossRef]
  51. Arokiyaraj, S.; Seo, S.S.; Kwon, M.; Lee, J.K.; Kim, M.K. Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: A longitudinal study. Sci. Rep. 2018, 8, 15479. [Google Scholar] [CrossRef] [PubMed]
  52. Happel, A.U.; Balle, C.; Havyarimana, E.; Brown, B.; Maust, B.S.; Feng, C.; Yi, B.H.; Gill, K.; Bekker, L.G.; Passmore, J.S.; et al. Cervicovaginal Human Papillomavirus Genomes, Microbiota Composition and Cytokine Concentrations in South African Adolescents. Viruses 2023, 15, 758. [Google Scholar] [CrossRef] [PubMed]
  53. Carter, K.A.; Srinivasan, S.; Fiedler, T.L.; Anzala, O.; Kimani, J.; Mochache, V.; Wallis, J.M.; Fredricks, D.N.; McClelland, R.S.; Balkus, J.E. Vaginal Bacteria and Risk of Incident and Persistent Infection With High-Risk Subtypes of Human Papillomavirus: A Cohort Study Among Kenyan Women. Sex. Transm. Dis. 2021, 48, 499–507. [Google Scholar] [CrossRef] [PubMed]
  54. Ma, Y.; Li, Y.; Liu, Y.; Cao, L.; Han, X.; Gao, S.; Zhang, C. Vaginal Microbiome Dysbiosis is Associated with the Different Cervical Disease Status. J. Microbiol. 2023, 61, 423–432. [Google Scholar] [CrossRef]
  55. Molina, M.A.; Leenders, W.P.J.; Huynen, M.A.; Melchers, W.J.G.; Andralojc, K.M. Temporal composition of the cervicovaginal microbiome associates with hrHPV infection outcomes in a longitudinal study. BMC Infect. Dis. 2024, 24, 552. [Google Scholar] [CrossRef]
  56. Chen, Y.; Qiu, X.; Wang, W.; Li, D.; Wu, A.; Hong, Z.; Di, W.; Qiu, L. Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort. BMC Infect. Dis. 2020, 20, 629. [Google Scholar] [CrossRef]
  57. So, K.A.; Yang, E.J.; Kim, N.R.; Hong, S.R.; Lee, J.H.; Hwang, C.S.; Shim, S.H.; Lee, S.J.; Kim, T.J. Changes of vaginal microbiota during cervical carcinogenesis in women with human papillomavirus infection. PLoS ONE 2020, 15, e0238705. [Google Scholar] [CrossRef]
  58. Kwasniewski, W.; Wolun-Cholewa, M.; Kotarski, J.; Warchol, W.; Kuzma, D.; Kwasniewska, A.; Gozdzicka-Jozefiak, A. Microbiota dysbiosis is associated with HPV-induced cervical carcinogenesis. Oncol. Lett. 2018, 16, 7035–7047. [Google Scholar] [CrossRef]
  59. Witkin, S.S.; Mendes-Soares, H.; Linhares, I.M.; Jayaram, A.; Ledger, W.J.; Forney, L.J. Influence of vaginal bacteria and D- and L-lactic acid isomers on vaginal extracellular matrix metalloproteinase inducer: Implications for protection against upper genital tract infections. mBio 2013, 4, e00460-13. [Google Scholar] [CrossRef]
  60. de Magalhães, C.C.B.; Linhares, I.M.; Masullo, L.F.; Eleutério, R.M.N.; Witkin, S.S.; Eleutério, J., Jr. Comparative measurement of D- and L-lactic acid isomers in vaginal secretions: Association with high-grade cervical squamous intraepithelial lesions. Arch. Gynecol. Obstet. 2022, 305, 373–377. [Google Scholar] [CrossRef]
  61. Yang, Z.; Zhang, Y.; Stubbe-Espejel, A.; Zhao, Y.; Liu, M.; Li, J.; Zhao, Y.; Tong, G.; Liu, N.; Qi, L.; et al. Vaginal microbiota and personal risk factors associated with HPV status conversion-A new approach to reduce the risk of cervical cancer? PLoS ONE 2022, 17, e0270521. [Google Scholar] [CrossRef] [PubMed]
  62. Gao, W.; Weng, J.; Gao, Y.; Chen, X. Comparison of the vaginal microbiota diversity of women with and without human papillomavirus infection: A cross-sectional study. BMC Infect. Dis. 2013, 13, 271. [Google Scholar] [CrossRef] [PubMed]
  63. Usyk, M.; Zolnik, C.P.; Castle, P.E.; Porras, C.; Herrero, R.; Gradissimo, A.; Gonzalez, P.; Safaeian, M.; Schiffman, M.; Burk, R.D. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. PLoS Pathog. 2020, 16, e1008376. [Google Scholar] [CrossRef]
  64. Yang, Z.; Wu, H.; Wang, X.; Tong, G.; Huang, Z.; Wang, J.; Jiang, Y.; Cao, M.; Wang, Y.; Deng, X.; et al. The Influence of Vaginal Microbiome and Clinical Factors on HPV Clearance: A Prospective Study. medRxiv 2022. [Google Scholar] [CrossRef]
  65. Nieves-Ramírez, M.E.; Partida-Rodríguez, O.; Moran, P.; Serrano-Vázquez, A.; Pérez-Juárez, H.; Pérez-Rodríguez, M.E.; Arrieta, M.C.; Ximénez-García, C.; Finlay, B.B. Cervical Squamous Intraepithelial Lesions Are Associated with Differences in the Vaginal Microbiota of Mexican Women. Microbiol. Spectr. 2021, 9, e0014321. [Google Scholar] [CrossRef]
  66. Chao, X.; Sun, T.; Wang, S.; Tan, X.; Fan, Q.; Shi, H.; Zhu, L.; Lang, J. Research of the potential biomarkers in vaginal microbiome for persistent high-risk human papillomavirus infection. Ann. Transl. Med. 2020, 8, 100. [Google Scholar] [CrossRef]
  67. Zheng, X.; Hu, N.; Liu, J.; Zhao, K.; Li, H.; Wang, J.; Zhang, M.; Zhang, L.; Song, L.; Lyu, Y.; et al. Cervicovaginal microbiota disorder combined with the change of cytosine phosphate guanine motif- toll like receptor 9 axis was associated with cervical cancerization. J. Cancer Res. Clin. Oncol. 2023, 149, 17371–17381. [Google Scholar] [CrossRef]
  68. Xu, X.; Zhang, Y.; Yu, L.; Shi, X.; Min, M.; Xiong, L.; Pan, J.; Liu, P.; Wu, G.; Gao, G. A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women. Sci. Rep. 2022, 12, 6609. [Google Scholar] [CrossRef]
  69. Wang, T.; Li, W.; Cai, M.; Ji, S.; Wang, Y.; Huang, N.; Jiang, Y.; Zhang, Z. Human papillomavirus molecular prevalence in south China and the impact on vaginal microbiome of unvaccinated women. mSystems 2024, 9, e0073824. [Google Scholar] [CrossRef]
  70. Shi, W.; Zhu, H.; Yuan, L.; Chen, X.; Huang, X.; Wang, K.; Li, Z. Vaginal microbiota and HPV clearance: A longitudinal study. Front. Oncol. 2022, 12, 955150. [Google Scholar] [CrossRef]
  71. Gomez Cherey, J.F.; Payalef, S.N.; Fleider, L.; Reyes, A.P.; Maldonado, V.A.; Losada, M.O.; Chen, X.; Cardinal, L.H.; Wang, Y.; Tatti, S.A.; et al. Microbiota unbalance in relation to high-risk human papillomavirus cervical infection. Int. J. Gynecol. Cancer 2023, 33, 482–488. [Google Scholar] [CrossRef] [PubMed]
  72. Oh, H.Y.; Kim, B.S.; Seo, S.S.; Kong, J.S.; Lee, J.K.; Park, S.Y.; Hong, K.M.; Kim, H.K.; Kim, M.K. The association of uterine cervical microbiota with an increased risk for cervical intraepithelial neoplasia in Korea. Clin. Microbiol. Infect. 2015, 21, e671–e679. [Google Scholar] [CrossRef]
  73. Seo, S.S.; Oh, H.Y.; Lee, J.K.; Kong, J.S.; Lee, D.O.; Kim, M.K. Combined effect of diet and cervical microbiome on the risk of cervical intraepithelial neoplasia. Clin. Nutr. 2016, 35, 1434–1441. [Google Scholar] [CrossRef] [PubMed]
  74. Lee, Y.H.; Kang, G.U.; Jeon, S.Y.; Tagele, S.B.; Pham, H.Q.; Kim, M.S.; Ahmad, S.; Jung, D.R.; Park, Y.J.; Han, H.S.; et al. Vaginal Microbiome-Based Bacterial Signatures for Predicting the Severity of Cervical Intraepithelial Neoplasia. Diagnostics 2020, 10, 1013. [Google Scholar] [CrossRef] [PubMed]
  75. Peremykina, A.; Cheranev, V.; Krivoy, A.; Andreev, A.O.; Repinskaia, Z.; Asaturova, A.V.; Korostin, D.; Rebrikov, D.; Bayramova, G.R. Microbiome markers in HPV-positive and HPV-negative women of reproductive age with ASCUS and SIL determined by V4 region of 16S rRNA gene sequencing. Front. Microbiol. 2024, 15, 1334502. [Google Scholar] [CrossRef]
  76. Teka, B.; Yoshida-Court, K.; Firdawoke, E.; Chanyalew, Z.; Gizaw, M.; Addissie, A.; Mihret, A.; Colbert, L.E.; Napravnik, T.C.; El Alam, M.B.; et al. Cervicovaginal Microbiota Profiles in Precancerous Lesions and Cervical Cancer among Ethiopian Women. Microorganisms 2023, 11, 833. [Google Scholar] [CrossRef]
  77. Wei, B.; Chen, Y.; Lu, T.; Cao, W.; Tang, Z.; Yang, H. Correlation between vaginal microbiota and different progression stages of cervical cancer. Genet. Mol. Biol. 2022, 45, e20200450. [Google Scholar] [CrossRef]
  78. Tosado-Rodríguez, E.; Mendez, L.B.; Espino, A.M.; Dorta-Estremera, S.; Aquino, E.E.; Romaguera, J.; Godoy-Vitorino, F. Inflammatory cytokines and a diverse cervicovaginal microbiota associate with cervical dysplasia in a cohort of Hispanics living in Puerto Rico. PLoS ONE 2023, 18, e0284673. [Google Scholar] [CrossRef]
  79. Fang, B.; Li, Q.; Wan, Z.; OuYang, Z.; Zhang, Q. Exploring the Association Between Cervical Microbiota and HR-HPV Infection Based on 16S rRNA Gene and Metagenomic Sequencing. Front. Cell Infect. Microbiol. 2022, 12, 922554. [Google Scholar] [CrossRef]
  80. Dong, Y.H.; Luo, Y.H.; Liu, C.J.; Huang, W.Y.; Feng, L.; Zou, X.Y.; Zhou, J.Y.; Li, X.R. Changes in microbial composition and interaction patterns of female urogenital tract and rectum in response to HPV infection. J. Transl. Med. 2024, 22, 125. [Google Scholar] [CrossRef]
  81. Zheng, J.J.; Miao, J.R.; Wu, Q.; Yu, C.X.; Mu, L.; Song, J.H. Correlation between HPV-negative cervical lesions and cervical microenvironment. Taiwan J. Obstet. Gynecol. 2020, 59, 855–861. [Google Scholar] [CrossRef] [PubMed]
  82. Cheng, L.; Norenhag, J.; Hu, Y.O.O.; Brusselaers, N.; Fransson, E.; Ährlund-Richter, A.; Guðnadóttir, U.; Angelidou, P.; Zha, Y.; Hamsten, M.; et al. Vaginal microbiota and human papillomavirus infection among young Swedish women. npj Biofilms Microbiomes 2020, 6, 39. [Google Scholar] [CrossRef] [PubMed]
  83. Liang, Y.; Chen, M.; Qin, L.; Wan, B.; Wang, H. A meta-analysis of the relationship between vaginal microecology, human papillomavirus infection and cervical intraepithelial neoplasia. Infect. Agents Cancer 2019, 14, 29. [Google Scholar] [CrossRef] [PubMed]
  84. Ogah, C.O.; Anikwe, C.C.; Ajah, L.O.; Ikeotuonye, A.C.; Lawani, O.L.; Okorochukwu, B.C.; Ikeoha, C.C.; Okoroafor, F.C. Preoperative vaginal cleansing with chlorhexidine solution in preventing post-cesarean section infections in a low resource setting: A randomized controlled trial. Acta Obstet. Gynecol. Scand. 2021, 100, 694–703. [Google Scholar] [CrossRef]
  85. Naidoo, K.; Abbai, N.; Tinarwo, P.; Sebitloane, M. BV associated bacteria specifically BVAB 1 and BVAB 3 as biomarkers for HPV risk and progression of cervical neoplasia. Infect. Dis. Obstet. Gynecol. 2022, 2022, 9562937. [Google Scholar] [CrossRef]
  86. Lebeau, A.; Bruyere, D.; Roncarati, P.; Peixoto, P.; Hervouet, E.; Cobraiville, G.; Taminiau, B.; Masson, M.; Gallego, C.; Mazzucchelli, G.; et al. HPV infection alters vaginal microbiome through down-regulating host mucosal innate peptides used by Lactobacilli as amino acid sources. Nat. Commun. 2022, 13, 1076. [Google Scholar] [CrossRef]
  87. Harwich, M.D., Jr.; Alves, J.M.; Buck, G.A.; Strauss, J.F., 3rd; Patterson, J.L.; Oki, A.T.; Girerd, P.H.; Jefferson, K.K. Drawing the line between commensal and pathogenic Gardnerella vaginalis through genome analysis and virulence studies. BMC Genom. 2010, 11, 375. [Google Scholar] [CrossRef]
  88. Fethers, K.; Twin, J.; Fairley, C.K.; Fowkes, F.J.; Garland, S.M.; Fehler, G.; Morton, A.M.; Hocking, J.S.; Tabrizi, S.N.; Bradshaw, C.S. Bacterial vaginosis (BV) candidate bacteria: Associations with BV and behavioural practices in sexually-experienced and inexperienced women. PLoS ONE 2012, 7, e30633. [Google Scholar] [CrossRef]
  89. Jimenez, N.R.; Mancilla, V.; Łaniewski, P.; Herbst-Kralovetz, M.M. Immunometabolic Contributions of Atopobiaceae Family Members in Human Papillomavirus Infection, Cervical Dysplasia and Cancer. J. Infect. Dis. 2024. online ahead of print. [Google Scholar] [CrossRef]
  90. Norenhag, J.; Edfeldt, G.; Stålberg, K.; Garcia, F.; Hugerth, L.W.; Engstrand, L.; Fransson, E.; Du, J.; Schuppe-Koistinen, I.; Olovsson, M. Compositional and functional differences of the vaginal microbiota of women with and without cervical dysplasia. Sci. Rep. 2024, 14, 11183. [Google Scholar] [CrossRef]
  91. Fracella, M.; Oliveto, G.; Sorrentino, L.; Roberto, P.; Cinti, L.; Viscido, A.; Di Lella, F.M.; Giuffrè, F.; Gentile, M.; Pietropaolo, V.; et al. Common Microbial Genital Infections and Their Impact on the Innate Immune Response to HPV in Cervical Cells. Pathogens 2022, 11, 1361. [Google Scholar] [CrossRef] [PubMed]
  92. Rosário, A.; Sousa, A.; Varandas, T.; Marinho-Dias, J.; Medeiros, R.; Martins, G.; Monteiro, P.; Sousa, H. Impact of cervicovaginal microbiome on the risk of cervical abnormalities development. J. Med. Virol. 2023, 95, e28762. [Google Scholar] [CrossRef] [PubMed]
  93. Godoy-Vitorino, F.; Romaguera, J.; Zhao, C.; Vargas-Robles, D.; Ortiz-Morales, G.; Vázquez-Sánchez, F.; Sanchez-Vázquez, M.; de la Garza-Casillas, M.; Martinez-Ferrer, M.; White, J.R.; et al. Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population. Front. Microbiol. 2018, 9, 2533. [Google Scholar] [CrossRef]
  94. Di Paola, M.; Sani, C.; Clemente, A.M.; Iossa, A.; Perissi, E.; Castronovo, G.; Tanturli, M.; Rivero, D.; Cozzolino, F.; Cavalieri, D.; et al. Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection. Sci. Rep. 2017, 7, 10200. [Google Scholar] [CrossRef]
  95. Chao, X.P.; Sun, T.T.; Wang, S.; Fan, Q.B.; Shi, H.H.; Zhu, L.; Lang, J.H. Correlation between the diversity of vaginal microbiota and the risk of high-risk human papillomavirus infection. Int. J. Gynecol. Cancer 2019, 29, 28–34. [Google Scholar] [CrossRef]
  96. Gottschick, C.; Deng, Z.L.; Vital, M.; Masur, C.; Abels, C.; Pieper, D.H.; Rohde, M.; Mendling, W.; Wagner-Döbler, I. Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis. Microbiome 2017, 5, 119. [Google Scholar] [CrossRef]
  97. Harwich, M.D., Jr.; Serrano, M.G.; Fettweis, J.M.; Alves, J.M.; Reimers, M.A.; Buck, G.A.; Jefferson, K.K. Genomic sequence analysis and characterization of Sneathia amnii sp. nov. BMC Genom. 2012, 13 (Suppl. 8), S4. [Google Scholar] [CrossRef]
  98. Dong, B.; Huang, Y.; Cai, H.; Chen, Y.; Li, Y.; Zou, H.; Lin, W.; Xue, H.; Feng, A.; Zhao, H.; et al. Prevotella as the hub of the cervicovaginal microbiota affects the occurrence of persistent human papillomavirus infection and cervical lesions in women of childbearing age via host NF-κB/C-myc. J. Med. Virol. 2022, 94, 5519–5534. [Google Scholar] [CrossRef]
  99. Gonçalves-Nobre, J.G.; Matos, A.; Carreira, M.; Santos, A.C.; Veiga, L.C.; Ginete, C.; Brito, M.; Pires, M.; Pereira, H.; Cardoso, C.; et al. The interplay between HPV, other Sexually Transmissible Infections and genital microbiome on cervical microenvironment (MicroCervixHPV study). Front. Cell Infect. Microbiol. 2023, 13, 1251913. [Google Scholar] [CrossRef]
  100. Zhang, N.; Chen, Z.; Huang, M.; Lu, Q.; Yang, H.; Xiang, J.; Yang, J.; Peng, Y.; Wang, G.; Han, N.; et al. Cervicovaginal microbiota long-term dynamics and prediction of different outcomes in persistent human papillomavirus infection. J. Med. Virol. 2024, 96, e29451. [Google Scholar] [CrossRef]
  101. Wei, Z.T.; Chen, H.L.; Wang, C.F.; Yang, G.L.; Han, S.M.; Zhang, S.L. Depiction of Vaginal Microbiota in Women With High-Risk Human Papillomavirus Infection. Front. Public Health 2020, 8, 587298. [Google Scholar] [CrossRef] [PubMed]
  102. Loonen, A.J.M.; Verhagen, F.; Luijten-de Vrije, I.; Lentjes-Beer, M.; Huijsmans, C.J.; van den Brule, A.J.C. Vaginal dysbiosis seems associated with hrHPV infection in women attending the Dutch Cervical Cancer Screening Program. Front. Cell Infect. Microbiol. 2024, 14, 1330844. [Google Scholar] [CrossRef] [PubMed]
  103. Chao, X.; Wang, L.; Wang, S.; Lang, J.; Tan, X.; Fan, Q.; Shi, H. Research of the Potential Vaginal Microbiome Biomarkers for High-Grade Squamous Intraepithelial Lesion. Front. Med. 2021, 8, 565001. [Google Scholar] [CrossRef] [PubMed]
  104. Kwon, M.; Seo, S.S.; Kim, M.K.; Lee, D.O.; Lim, M.C. Compositional and Functional Differences between Microbiota and Cervical Carcinogenesis as Identified by Shotgun Metagenomic Sequencing. Cancers 2019, 11, 309. [Google Scholar] [CrossRef]
  105. Zhang, C.; Liu, Y.; Gao, W.; Pan, Y.; Gao, Y.; Shen, J.; Xiong, H. The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia. Cancer Med. 2018, 7, 2172–2179. [Google Scholar] [CrossRef]
  106. Lin, S.; Zhang, B.; Lin, Y.; Lin, Y.; Zuo, X. Dysbiosis of Cervical and Vaginal Microbiota Associated With Cervical Intraepithelial Neoplasia. Front. Cell Infect. Microbiol. 2022, 12, 767693. [Google Scholar] [CrossRef]
  107. Liu, Y.; Wang, S.; Liu, J.; Su, M.; Diao, X.; Liang, X.; Zhang, J.; Wang, Q.; Zhan, Y. Characteristics of vaginal microbiota in various cervical intraepithelial neoplasia: A cross-sectional study. J. Transl. Med. 2023, 21, 816. [Google Scholar] [CrossRef]
  108. Kaliterna, V.; Kaliterna, P.; Pejkovic, L.; Vulic, R.; Zanchi, L.; Cerskov, K. Prevalence of Human Papillomavirus (HPV) among Females in the General Population of the Split and Dalmatia County and Its Association with Genital Microbiota and Infections: A Prospective Study. Viruses 2023, 15, 443. [Google Scholar] [CrossRef]
  109. Lv, P.; Zhao, F.; Xu, X.; Xu, J.; Wang, Q.; Zhao, Z. Correlation between Common Lower Genital Tract Microbes and High-Risk Human Papillomavirus Infection. Can. J. Infect. Dis. Med. Microbiol. 2019, 2019, 9678104. [Google Scholar] [CrossRef]
  110. Cortés-Ortíz, I.A.; Puente-Rivera, J.; Ordaz-Pérez, G.; Bonilla-Cortés, A.Y.; Figueroa-Arredondo, P.; Serrano-Bello, C.A.; García-Moncada, E.; Acosta-Altamirano, G.; Artigas-Pérez, D.E.; Bravata-Alcántara, J.C.; et al. Brachybacterium conglomeratum Is Associated with Cervicovaginal Infections and Human Papilloma Virus in Cervical Disease of Mexican Female Patients. Microorganisms 2023, 11, 2769. [Google Scholar] [CrossRef]
  111. Yang, M.; Li, L.; Jiang, C.; Qin, X.; Zhou, M.; Mao, X.; Xing, H. Co-infection with trichomonas vaginalis increases the risk of cervical intraepithelial neoplasia grade 2-3 among HPV16 positive female: A large population-based study. BMC Infect. Dis. 2020, 20, 642. [Google Scholar] [CrossRef] [PubMed]
  112. Hamar, B.; Teutsch, B.; Hoffmann, E.; Hegyi, P.; Váradi, A.; Nyirády, P.; Hunka, Z.; Ács, N.; Lintner, B.; Hermánné, R.J.; et al. Trichomonas vaginalis infection is associated with increased risk of cervical carcinogenesis: A systematic review and meta-analysis of 470 000 patients. Int. J. Gynaecol. Obstet. 2023, 163, 31–43. [Google Scholar] [CrossRef] [PubMed]
  113. Zheng, J.; Zhao, R.; Deng, C. Correlation analysis of vaginal flora and immune function Th1/Th2 imbalance in women with high-risk HPV infections in the female reproductive tract. Cell. Mol. Biol. 2024, 70, 128–133. [Google Scholar] [CrossRef] [PubMed]
  114. Silins, I.; Ryd, W.; Strand, A.; Wadell, G.; Törnberg, S.; Hansson, B.G.; Wang, X.; Arnheim, L.; Dahl, V.; Bremell, D.; et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int. J. Cancer 2005, 116, 110–115. [Google Scholar] [CrossRef]
  115. Grieshaber, S.S.; Grieshaber, N.A.; Miller, N.; Hackstadt, T. Chlamydia trachomatis causes centrosomal defects resulting in chromosomal segregation abnormalities. Traffic 2006, 7, 940–949. [Google Scholar] [CrossRef]
  116. Verteramo, R.; Pierangeli, A.; Mancini, E.; Calzolari, E.; Bucci, M.; Osborn, J.; Nicosia, R.; Chiarini, F.; Antonelli, G.; Degener, A.M. Human Papillomaviruses and genital co-infections in gynaecological outpatients. BMC Infect. Dis. 2009, 9, 16. [Google Scholar] [CrossRef]
  117. Borgdorff, H.; Gautam, R.; Armstrong, S.D.; Xia, D.; Ndayisaba, G.F.; van Teijlingen, N.H.; Geijtenbeek, T.B.; Wastling, J.M.; van de Wijgert, J.H. Cervicovaginal microbiome dysbiosis is associated with proteome changes related to alterations of the cervicovaginal mucosal barrier. Mucosal Immunol. 2016, 9, 621–633. [Google Scholar] [CrossRef]
  118. Chen, X.; He, H.; Xiao, Y.; Hasim, A.; Yuan, J.; Ye, M.; Li, X.; Hao, Y.; Guo, X. CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways. Front. Oncol. 2021, 11, 629350. [Google Scholar] [CrossRef]
  119. Paehler Vor der Holte, A.; Fangk, I.; Glombitza, S.; Wilkens, L.; Welkoborsky, H.J. Impact of human papillomaviruses (HPV) on recurrence rate and malignant progression of sinonasal papillomas. Cancer Med. 2021, 10, 634–641. [Google Scholar] [CrossRef]
  120. Lazenby, G.B.; Taylor, P.T.; Badman, B.S.; McHaki, E.; Korte, J.E.; Soper, D.E.; Young Pierce, J. An association between Trichomonas vaginalis and high-risk human papillomavirus in rural Tanzanian women undergoing cervical cancer screening. Clin. Ther. 2014, 36, 38–45. [Google Scholar] [CrossRef]
  121. Tong, W.W.; Shepherd, K.; Garland, S.; Meagher, A.; Templeton, D.J.; Fairley, C.K.; Jin, F.; Poynten, I.M.; Zaunders, J.; Hillman, R.J.; et al. Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions. J. Infect. Dis. 2015, 211, 405–415. [Google Scholar] [CrossRef] [PubMed]
  122. Cortés-Alaguero, C.; González-Mirasol, E.; Morales-Roselló, J.; Poblet-Martinez, E. Do clinical data and human papilloma virus genotype influence spontaneous regression in grade I cervical intraepithelial neoplasia? J. Turk. Ger. Gynecol. Assoc. 2017, 18, 1–8. [Google Scholar] [CrossRef] [PubMed]
  123. Ma, M.; Feng, Y.; Fan, P.; Yao, X.; Peng, Y.; Dong, T.; Wang, R. Human papilloma virus E1-specific T cell immune response is associated with the prognosis of cervical cancer patients with squamous cell carcinoma. Infect. Agents Cancer 2018, 13, 35. [Google Scholar] [CrossRef]
  124. Al-Taei, S.; Banner, R.; Powell, N.; Evans, M.; Palaniappan, N.; Tabi, Z.; Man, S. Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy. Cancer Immunol. Immunother. 2013, 62, 1821–1830. [Google Scholar] [CrossRef]
  125. Masterson, L.; Lechner, M.; Loewenbein, S.; Mohammed, H.; Davies-Husband, C.; Fenton, T.; Sudhoff, H.; Jani, P.; Goon, P.; Sterling, J. CD8(+) T cell response to human papillomavirus 16 E7 is able to predict survival outcome in oropharyngeal cancer. Eur. J. Cancer 2016, 67, 141–151. [Google Scholar] [CrossRef]
  126. Wang, Q.; Qin, W.; Gao, W.; Zhao, K.; Pan, X.; Jiang, X.; Zhao, J. Correlation between vaginal flora and cervical immune function of human papilloma virus-infected patients with cervical cancer. Afr. Health Sci. 2023, 23, 179–185. [Google Scholar] [CrossRef]
  127. Łaniewski, P.; Cui, H.; Roe, D.J.; Barnes, D.; Goulder, A.; Monk, B.J.; Greenspan, D.L.; Chase, D.M.; Herbst-Kralovetz, M.M. Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis. Sci. Rep. 2019, 9, 7333. [Google Scholar] [CrossRef]
  128. Nicolò, S.; Tanturli, M.; Mattiuz, G.; Antonelli, A.; Baccani, I.; Bonaiuto, C.; Baldi, S.; Nannini, G.; Menicatti, M.; Bartolucci, G.; et al. Vaginal Lactobacilli and Vaginal Dysbiosis-Associated Bacteria Differently Affect Cervical Epithelial and Immune Homeostasis and Anti-Viral Defenses. Int. J. Mol. Sci. 2021, 22, 6487. [Google Scholar] [CrossRef]
  129. Zheng, J.J.; Song, J.H.; Yu, C.X.; Wang, F.; Wang, P.C.; Meng, J.W. Difference in vaginal microecology, local immunity and HPV infection among childbearing-age women with different degrees of cervical lesions in Inner Mongolia. BMC Womens Health 2019, 19, 109. [Google Scholar] [CrossRef]
  130. Shannon, B.; Yi, T.J.; Perusini, S.; Gajer, P.; Ma, B.; Humphrys, M.S.; Thomas-Pavanel, J.; Chieza, L.; Janakiram, P.; Saunders, M.; et al. Association of HPV infection and clearance with cervicovaginal immunology and the vaginal microbiota. Mucosal Immunol. 2017, 10, 1310–1319. [Google Scholar] [CrossRef]
  131. Wang, W.; Yu, X.; Wu, C.; Jin, H. IL-36γ inhibits differentiation and induces inflammation of keratinocyte via Wnt signaling pathway in psoriasis. Int. J. Med. Sci. 2017, 14, 1002–1007. [Google Scholar] [CrossRef] [PubMed]
  132. Golijow, C.D.; Abba, M.C.; Mourón, S.A.; Laguens, R.M.; Dulout, F.N.; Smith, J.S. Chlamydia trachomatis and Human papillomavirus infections in cervical disease in Argentine women. Gynecol. Oncol. 2005, 96, 181–186. [Google Scholar] [CrossRef] [PubMed]
  133. Yang, Y.; Zhu, J.; Feng, R.; Han, M.; Chen, F.; Hu, Y. Altered vaginal cervical microbiota diversity contributes to HPV-induced cervical cancer via inflammation regulation. PeerJ 2024, 12, e17415. [Google Scholar] [CrossRef] [PubMed]
  134. Lu, X. Impact of IL-12 in Cancer. Curr. Cancer Drug Targets 2017, 17, 682–697. [Google Scholar] [CrossRef]
  135. Si, J.; You, H.J.; Yu, J.; Sung, J.; Ko, G. Prevotella as a Hub for Vaginal Microbiota under the Influence of Host Genetics and Their Association with Obesity. Cell Host Microbe 2017, 21, 97–105. [Google Scholar] [CrossRef]
  136. Pybus, V.; Onderdonk, A.B. Evidence for a commensal, symbiotic relationship between Gardnerella vaginalis and Prevotella bivia involving ammonia: Potential significance for bacterial vaginosis. J. Infect. Dis. 1997, 175, 406–413. [Google Scholar] [CrossRef]
  137. Kaur, U.S.; Shet, A.; Rajnala, N.; Gopalan, B.P.; Moar, P.D.H.; Singh, B.P.; Chaturvedi, R.; Tandon, R. High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy. Sci. Rep. 2018, 8, 17679. [Google Scholar] [CrossRef]
  138. Ruffilli, I.; Ferrari, S.M.; Colaci, M.; Ferri, C.; Fallahi, P.; Antonelli, A. IP-10 in autoimmune thyroiditis. Horm. Metab. Res. 2014, 46, 597–602. [Google Scholar] [CrossRef]
  139. Hoermannsperger, G.; Clavel, T.; Hoffmann, M.; Reiff, C.; Kelly, D.; Loh, G.; Blaut, M.; Hölzlwimmer, G.; Laschinger, M.; Haller, D. Post-translational inhibition of IP-10 secretion in IEC by probiotic bacteria: Impact on chronic inflammation. PLoS ONE 2009, 4, e4365. [Google Scholar] [CrossRef]
  140. von Schillde, M.A.; Hörmannsperger, G.; Weiher, M.; Alpert, C.A.; Hahne, H.; Bäuerl, C.; van Huynegem, K.; Steidler, L.; Hrncir, T.; Pérez-Martínez, G.; et al. Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. Cell Host Microbe 2012, 11, 387–396. [Google Scholar] [CrossRef]
  141. Usyk, M.; Schlecht, N.F.; Pickering, S.; Williams, L.; Sollecito, C.C.; Gradissimo, A.; Porras, C.; Safaeian, M.; Pinto, L.; Herrero, R.; et al. molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history. Nat. Commun. 2022, 13, 233. [Google Scholar] [CrossRef] [PubMed]
  142. Libby, E.K.; Pascal, K.E.; Mordechai, E.; Adelson, M.E.; Trama, J.P. Atopobium vaginae triggers an innate immune response in an in vitro model of bacterial vaginosis. Microbes Infect. 2008, 10, 439–446. [Google Scholar] [CrossRef] [PubMed]
  143. Doerflinger, S.Y.; Throop, A.L.; Herbst-Kralovetz, M.M. Bacteria in the vaginal microbiome alter the innate immune response and barrier properties of the human vaginal epithelia in a species-specific manner. J. Infect. Dis. 2014, 209, 1989–1999. [Google Scholar] [CrossRef] [PubMed]
  144. Wohlmeister, D.; Vianna, D.R.; Helfer, V.E.; Gimenes, F.; Consolaro, M.E.; Barcellos, R.B.; Rossetti, M.L.; Calil, L.N.; Buffon, A.; Pilger, D.A. Association of human papillomavirus and Chlamydia trachomatis with intraepithelial alterations in cervix samples. Mem. Inst. Oswaldo Cruz 2016, 111, 106–113. [Google Scholar] [CrossRef]
  145. Schutyser, E.; Struyf, S.; Van Damme, J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor. Rev. 2003, 14, 409–426. [Google Scholar] [CrossRef]
  146. Loopik, D.L.; Bentley, H.A.; Eijgenraam, M.N.; IntHout, J.; Bekkers, R.L.M.; Bentley, J.R. The Natural History of Cervical Intraepithelial Neoplasia Grades 1, 2, and 3: A Systematic Review and Meta-analysis. J. Low. Genit. Tract. Dis. 2021, 25, 221–231. [Google Scholar] [CrossRef]
  147. Martin-Hirsch, P.P.; Paraskevaidis, E.; Bryant, A.; Dickinson, H.O. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst. Rev. 2013, 2013, Cd001318. [Google Scholar] [CrossRef]
  148. Conner, S.N.; Frey, H.A.; Cahill, A.G.; Macones, G.A.; Colditz, G.A.; Tuuli, M.G. Loop electrosurgical excision procedure and risk of preterm birth: A systematic review and meta-analysis. Obstet. Gynecol. 2014, 123, 752–761. [Google Scholar] [CrossRef]
  149. Loopik, D.L.; van Drongelen, J.; Bekkers, R.L.M.; Voorham, Q.J.M.; Melchers, W.J.G.; Massuger, L.; van Kemenade, F.J.; Siebers, A.G. Cervical intraepithelial neoplasia and the risk of spontaneous preterm birth: A Dutch population-based cohort study with 45,259 pregnancy outcomes. PLoS Med. 2021, 18, e1003665. [Google Scholar] [CrossRef]
  150. Grimm, C.; Polterauer, S.; Natter, C.; Rahhal, J.; Hefler, L.; Tempfer, C.B.; Heinze, G.; Stary, G.; Reinthaller, A.; Speiser, P. Treatment of cervical intraepithelial neoplasia with topical imiquimod: A randomized controlled trial. Obstet. Gynecol. 2012, 120, 152–159. [Google Scholar] [CrossRef]
  151. van de Sande, A.J.M.; Kengsakul, M.; Koeneman, M.M.; Jozwiak, M.; Gerestein, C.G.; Kruse, A.J.; van Esch, E.M.G.; de Vos van Steenwijk, P.J.; Muntinga, C.L.P.; Bramer, W.M.; et al. The efficacy of topical imiquimod in high-grade cervical intraepithelial neoplasia: A systematic review and meta-analysis. Int. J. Gynaecol. Obstet. 2024, 164, 66–74. [Google Scholar] [CrossRef] [PubMed]
  152. Hendriks, N.; Koeneman, M.M.; van de Sande, A.J.M.; Penders, C.G.J.; Piek, J.M.J.; Kooreman, L.F.S.; van Kuijk, S.M.J.; Hoosemans, L.; Sep, S.J.S.; de Vos Van Steenwijk, P.J.; et al. Topical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasia (TOPIC-3): A Nonrandomized Multicenter Study. J. Immunother. 2022, 45, 180–186. [Google Scholar] [CrossRef] [PubMed]
  153. Zhang, H.; Lu, J.; Lu, Y.; Cai, Q.; Liu, H.; Xu, C. Cervical microbiome is altered in cervical intraepithelial neoplasia after loop electrosurgical excision procedure in china. Sci. Rep. 2018, 8, 4923. [Google Scholar] [CrossRef]
  154. Giovannetti, O.; Tomalty, D.; Velikonja, L.; Gray, G.; Boev, N.; Gilmore, S.; Oladipo, J.; Sjaarda, C.; Sheth, P.M.; Adams, M.A. Pre- and post-LEEP: Analysis of the female urogenital tract microenvironment and its association with sexual dysfunction. Sex. Med. 2023, 11, qfad039. [Google Scholar] [CrossRef]
  155. Wiik, J.; Sengpiel, V.; Kyrgiou, M.; Nilsson, S.; Mitra, A.; Tanbo, T.; Monceyron Jonassen, C.; Møller Tannæs, T.; Sjøborg, K. Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study. BMC Womens Health 2019, 19, 30. [Google Scholar] [CrossRef]
  156. Caselli, E.; D’Accolti, M.; Santi, E.; Soffritti, I.; Conzadori, S.; Mazzacane, S.; Greco, P.; Contini, C.; Bonaccorsi, G. Vaginal Microbiota and Cytokine Microenvironment in HPV Clearance/Persistence in Women Surgically Treated for Cervical Intraepithelial Neoplasia: An Observational Prospective Study. Front. Cell Infect. Microbiol. 2020, 10, 540900. [Google Scholar] [CrossRef]
  157. Kawahara, R.; Fujii, T.; Kukimoto, I.; Nomura, H.; Kawasaki, R.; Nishio, E.; Ichikawa, R.; Tsukamoto, T.; Iwata, A. Changes to the cervicovaginal microbiota and cervical cytokine profile following surgery for cervical intraepithelial neoplasia. Sci. Rep. 2021, 11, 2156. [Google Scholar] [CrossRef]
  158. DI Pierro, F.; Criscuolo, A.A.; Dei Giudici, A.; Senatori, R.; Sesti, F.; Ciotti, M.; Piccione, E. Oral administration of Lactobacillus crispatus M247 to papillomavirus-infected women: Results of a preliminary, uncontrolled, open trial. Minerva Obstet. Gynecol. 2021, 73, 621–631. [Google Scholar] [CrossRef]
  159. Dellino, M.; Cascardi, E.; Laganà, A.S.; Di Vagno, G.; Malvasi, A.; Zaccaro, R.; Maggipinto, K.; Cazzato, G.; Scacco, S.; Tinelli, R.; et al. Lactobacillus crispatus M247 oral administration: Is it really an effective strategy in the management of papillomavirus-infected women? Infect. Agents Cancer 2022, 17, 53. [Google Scholar] [CrossRef]
  160. Liu, Y.; Zhao, X.; Wu, F.; Chen, J.; Luo, J.; Wu, C.; Chen, T. Effectiveness of vaginal probiotics Lactobacillus crispatus chen-01 in women with high-risk HPV infection: A prospective controlled pilot study. Aging 2024, 16, 11446–11459. [Google Scholar] [CrossRef]
  161. Abdulrahman, Z.; Hendriks, N.; J Kruse, A.; Somarakis, A.; J M van de Sande, A.; J van Beekhuizen, H.; M J Piek, J.; de Miranda, N.F.C.C.; Kooreman, L.F.S.; F M Slangen, B.; et al. Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions. J. Immunother. Cancer 2022, 10, e005288. [Google Scholar] [CrossRef] [PubMed]
  162. Fan, Z.; Han, D.; Fan, X.; Zeng, Y.; Zhao, L. Analysis of the correlation between cervical HPV infection, cervical lesions and vaginal microecology. Front. Cell Infect. Microbiol. 2024, 14, 1405789. [Google Scholar] [CrossRef]
Figure 1. Flow diagram of review process.
Figure 1. Flow diagram of review process.
Ijms 26 03954 g001
Table 1. Overview of vaginal community state types.
Table 1. Overview of vaginal community state types.
Community State Type (CST)Dominant Species
CST ILactobacillus crispatus
CST IILactobacillus gasseri
CST IIILactobacillus iners
CST IVDiverse bacteria, not dominated by Lactobacillus
CST VLactobacillus jensenii
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Schellekens, H.C.J.; Schmidt, L.M.S.; Morré, S.A.; van Esch, E.M.G.; de Vos van Steenwijk, P.J. Vaginal Microbiota and Local Immunity in HPV-Induced High-Grade Cervical Dysplasia: A Narrative Review. Int. J. Mol. Sci. 2025, 26, 3954. https://doi.org/10.3390/ijms26093954

AMA Style

Schellekens HCJ, Schmidt LMS, Morré SA, van Esch EMG, de Vos van Steenwijk PJ. Vaginal Microbiota and Local Immunity in HPV-Induced High-Grade Cervical Dysplasia: A Narrative Review. International Journal of Molecular Sciences. 2025; 26(9):3954. https://doi.org/10.3390/ijms26093954

Chicago/Turabian Style

Schellekens, Helena C. J., Lotte M. S. Schmidt, Servaas A. Morré, Edith M. G. van Esch, and Peggy J. de Vos van Steenwijk. 2025. "Vaginal Microbiota and Local Immunity in HPV-Induced High-Grade Cervical Dysplasia: A Narrative Review" International Journal of Molecular Sciences 26, no. 9: 3954. https://doi.org/10.3390/ijms26093954

APA Style

Schellekens, H. C. J., Schmidt, L. M. S., Morré, S. A., van Esch, E. M. G., & de Vos van Steenwijk, P. J. (2025). Vaginal Microbiota and Local Immunity in HPV-Induced High-Grade Cervical Dysplasia: A Narrative Review. International Journal of Molecular Sciences, 26(9), 3954. https://doi.org/10.3390/ijms26093954

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop